Please ensure Javascript is enabled for purposes of website accessibility

Here's What Caused Rigel Pharmaceuticals' Wild Ride Today

By Todd Campbell – Updated Apr 12, 2018 at 4:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A pivotal decision is fast approaching, but it was a mistake that sent the shares soaring.

What happened

After a third-party administrator of Rigel Pharmaceuticals' (RIGL -4.10%) investor relations website posted incorrect information about its lead drug candidate, shares in the clinical-stage biotech rocketed upward by as much as 40% before settling to a 16.7% gain on Thursday. 

So what

Rigel Pharmaceuticals doesn't have any drugs on the market yet, but it could win approval for its first therapy soon. An FDA decision on Tavalisse is expected on April 17.

A man in a suit scratches his head while staring at diagrams on a chalkboard.

IMAGE SOURCE: GETTY IMAGES.

Although the decision isn't expected for a few more days, eagle-eyed investors jumped to buy shares after noticing a post on the company's website describing Tavalisse as "the company's first FDA approved product."

The posting, however, was a mistake. According to a Rigel Pharmaceuticals statement, an error by the external host of its investor relations website resulted in the information being shared. The company has since removed the post and management says that "the FDA is continuing its review of the NDA [New Drug Application]."

Now what

Mistakes happen, but this one could prove costly if the FDA doesn't wind up approving Tavalisse and shares end up sinking as a result.

It's certainly possible that the inadvertent posting was simply an update to the website that was supposed to go live following the formal announcement, but that's guesswork, and there's no guarantee that an OK is forthcoming.

Nevertheless, there is an opportunity for Rigel to make the transition from clinical-stage to commercial-stage company, and Tavalisse could contribute meaningful revenue someday if it does get a green light. The drug is under review as a treatment for ITP, a disorder in which the immune system attacks blood platelets, resulting in abnormally low platelet counts.

The addressable market is 100,000 patients, and for many, the current treatment of steroids or spleen removal are far from ideal. Trial results suggest that Tavalisse could provide doctors with a convenient oral formulation that doesn't require weekly office visits or dietary restrictions. Those advantages could lead to the drug's becoming an important treatment option.

Overall, we'll know soon enough if Tavalisse is a go or not. Perhaps, it's best to wait on the sidelines, though -- until we know for sure that the FDA has signed off on the treatment.

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rigel Pharmaceuticals, Inc. Stock Quote
Rigel Pharmaceuticals, Inc.
RIGL
$1.17 (-4.10%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.